News · November 15, 2026
Retatrutide Phase 3: 28.3% Weight Loss at 80 Weeks (Nov 2026)
Lilly's retatrutide Phase 3 results in numbers: 28.3% weight loss at 80 weeks, the head-to-head with Ozempic, and why it is not approved or sold legally yet.
By Julian Caraulani · Published November 20, 2026 · Updated November 20, 2026
Key numbers
- TRIUMPH-1 result
- 28.3% average weight loss at 80 weeks on the highest dose (25.0% counting everyone randomized)
- Head to head
- 20% to 21% weight loss vs 9% on Ozempic at 80 weeks (TRANSCEND-T2D-2)
- Latest event
- Phase 3 data presented at ObesityWeek, 15 Nov 2026
- FDA status
- Not approved. Lilly plans to submit in Q1 2027
- Where to get it
- Only in Lilly's clinical trials
- Announced by
- Eli Lilly and Company
What happened
Eli Lilly's retatrutide is a weekly injection that acts on three hormone receptors (GIP, GLP-1 and glucagon). In 2026 Lilly reported a run of Phase 3 results, and on 15 November it presented TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 data at ObesityWeek in Washington (Lilly).
| Trial (Lilly release) | Who | Result at 80 weeks |
|---|---|---|
| TRIUMPH-1 (21 May 2026) | 2,339 adults with obesity or overweight, no diabetes | Highest dose 28.3% average weight loss vs 2.2% on placebo; 25.0% vs 3.9% counting everyone randomized |
| TRIUMPH-1 extension | 532 people with a BMI of 35 or more | Up to 30.3% at 104 weeks |
| TRIUMPH-2 (29 Sep 2026) | Adults with obesity and type 2 diabetes | Highest dose 20.8% average weight loss |
| TRANSCEND-T2D-2 (28 Oct 2026) | Adults with type 2 diabetes, vs Ozempic | 20% to 21% weight loss vs 9%; A1C down 2.2 vs 1.8 points |
In TRIUMPH-1, 45.3% of people on the highest dose lost at least 30% of their body weight. The most common side effects were stomach-related: nausea in 42.4% on the highest dose vs 14.8% on placebo, and vomiting in 25.3% vs 4.8% (Lilly).
Two points sit next to those numbers. The headline figures assume people stayed on treatment; Lilly also reports the lower "everyone randomized" figure, shown above. And most of these results are press releases; detailed papers follow at medical meetings and in journals. Our retatrutide vs semaglutide guide goes through the head-to-head trial in depth.
What this means for cost
There is no legal price for retatrutide today. It is not FDA-approved, Lilly says it "is legally available only to participants in Lilly's clinical trials" (Lilly), and the October 2026 HHS peptide policy does not cover it. Vials sold online as research retatrutide are not the drug tested in these trials. No program on this site sells it, and none will until FDA approves it.
If you want a weight-related peptide program now, the peptides for weight loss guide covers what licensed programs prescribe, and the cost page lists every program's dated price.
What happens next
- Q1 2027
Lilly plans to submit a Biologics License Application for retatrutide to FDA, after completing its manufacturing (CMC) data package (Lilly, 23 Jul 2026).
- After submission
FDA review. No decision date exists yet; a decision is not expected before the filing.
- 2027
More detailed Phase 3 papers and meeting presentations, per Lilly.
Sources
- Eli Lilly, TRIUMPH-1 topline release, 21 May 2026, read November 20, 2026
- Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline release with Q1 2027 filing plan, 23 Jul 2026, read November 20, 2026
- Eli Lilly, TRIUMPH-2 detailed results, 29 Sep 2026, read November 20, 2026
- Eli Lilly press releases: TRANSCEND-T2D-2 head-to-head, 28 Oct 2026, read November 20, 2026
- Eli Lilly, ObesityWeek 2026 presentations, 14 Nov 2026, read November 20, 2026